In addition to its discovery-stage FMRP program, Opna Bio is targeting master regulators to advance the treatment of cancer. These include OPN-6602, a best-in-class EP300/CBP inhibitor, currently in preclinical development and expected to enter the clinic in 2024.
EXPLORE
Hanahan et al, November 2022
Upregulation of the neuronal fragile-X mental retardation protein in cancer cells suppresses proinflammatory signals to circumvent tumor immunity
Read MoreOPN-6602 Expected to Begin Phase 1 Clinical Study in Multiple Myeloma in Summer 2024
